Revvity Inc. (RVTY)

Rating: HOLD

HOLD (5-tier) · mature cash generator · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -3% vs spot
• Monte Carlo median implies -10% vs spot
• DCF fair value implies -24% vs spot
• Bear case (Structural — Reimbursement / Competition / GLP-1 Procedure Hit) downside is -52% vs spot
• Net: reward/risk of 0.3× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At $111.26 on a forward P/E near 20.6x, the market prices Revvity as a steady mid-cycle diagnostics and life-science-tools compounder: mid-single-digit organic growth, a mid-20s operating margin, and disciplined capital return. The engine broadly agrees, and that is the point. Triangulation lands the probability-weighted target at $113.40, essentially at spot, so the rating is HOLD rather than a directional call. Three anchors bracket it: the DCF at roughly $85 on an 8.5% WACC and 18x terminal, peer-median EV/revenue and forward P/E near $100-103, and the scenario ladder centred on a $117.68 base. The base assumes 5% growth and a 23.6% margin; the multiple, not earnings, carries most of the Monte Carlo variance at 65%. Capex is light at low-2% of revenue, so free-cash conversion is high and the balance-sheet net-debt of $2.49B is serviceable. The single most damaging risk is multiple compression: with valuation, not fundamentals, doing the work, a de-rating toward peer-median levels removes the modest upside without any change in the operating story.

The dashboard below is the whole argument on one page: spot ($112) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear is the reset, not the recession. Combine the 20% structural and 17% cyclical weights and the reimbursement/funding/utilization-reset state carries the plurality. Its mechanism is concrete. Biopharma R&D budgets and hospital capital spending fund a large share of Revvity's reagent and instrument demand; both are rate- and grant-sensitive and can contract together. Two or three quarters of flat-to-negative organic growth would drag the 23.6% margin toward the low-20s as fixed cost deleverages, and the market would re-rate a slower compounder from 20x toward the low-teens seen in the structural path. Earnings and the multiple then fall in tandem, which is how the $49.90 structural target lands below the 52-week low of $81.19.

Key Debate

P/E Multiple explains 65% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.46 vs analyst floor +0.00 → delta +0.46 (n=20 mgmt / 13 Q&A; 66th pctile across the S&P book, z +0.4).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 838 articles): avg ticker sentiment +0.17 (bullish 29% / bearish 5%)

Scenario Analysis

The tree runs from a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($54) to a 'Bull — Re-Rate' bull case ($191); the probability-weighted blend (PWEV $108) is -3% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $54). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 49.9; probability: 0.2.
• Hospital-Capex / Utilization Recession (17%, $84). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising. Drivers — implied_target: 84.73; probability: 0.17.
• Base — Procedure Volume + Innovation (35%, $108). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns. Drivers — implied_target: 117.68; probability: 0.35.
• Growth — New-Product Cycle / Penetration (20%, $150). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 158.87; probability: 0.2.
• Bull — Re-Rate (8%, $191). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration. Drivers — implied_target: 200.65; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $101 and 39% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (65% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 18x terminal FCF multiple → $86. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 19.03x) implies $103. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 22% of the median — moderate (healthy method disagreement — read the blend with care).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Devices Tools

This name sits in the Health Devices Tools as a medical_devices. procedure volumes + product-innovation cycle + hospital capital spending Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)

Mapping note: name-level 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) + 'Hospital-Capex / Utilization Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — New-Product Cycle / Penetration' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $3B + PV(terminal) $9B = EV $12B; + net cash → equity $10B ÷ diluted shares 0.11B = $86/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $81/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 39% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $103; EV/Rev → $99.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 21x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0.8% of revenue; cash conversion (OCF/NI) 242% — cash-backed.

Catalyst Calendar

• 2026-07-27 (~19d) — Quarterly earnings — est. EPS $1.23 (AV EARNINGS_CALENDAR)
• 2026-10-08 (~92d) — New diagnostics/immunoassay or newborn-screening menu expansion launch (authored)
• 2026-12-03 (~148d) — China life-science stimulus / academic-and-pharma funding data point (authored)
• 2027-02-03 (~210d) — FY2026 results with organic-growth split (diagnostics vs life-science solutions) and pharma-R&D demand read (authored)

Forecast Track Record

• EPS surprise: beat 100.0% of the last 8 quarters; average surprise +6.4%.

Competitive Moat

Narrow moat. Revvity's installed instrument base with recurring reagents/consumables (razor-and-blade) and its newborn-screening and immunodiagnostics franchises give a narrow-to-wide moat, but it competes against much larger life-science-tools peers (Thermo, Danaher); the falsifiable claim is that if consumable pull-through weakens or the diagnostics franchises lose share, the moat is only narrow and the ~20.6x forward multiple should compress toward the tools-peer ~17-18x rather than re-rate higher.

Moat sources:

• installed instrument base pulling recurring reagent/consumable revenue (razor-and-blade attach)
• newborn-screening and immunodiagnostics franchises with regulatory/reference-lab embedding
• software/informatics (Signals) attach raising workflow switching cost
• reference relationships in clinical labs and pharma R&D that lock in assay standards

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 19.2× forward EPS, vs the house DCF terminal 18.0×, and a peer median 19.03×. The house DCF sits 24% below spot, so the market is pricing in more than the house case — roughly 2.2pp of revenue CAGR.

Variant perception: the house view is in-line with consensus, and the thesis is primarily growth-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 19.8× (simple median 19.03×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $81–$118, centre $98 (-13% vs spot); spot sits at the 83th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Re-Rate): $191.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (28.0); Terminal × ±15% (25.0); Op margin ±3pp (25.0); WACC ±1pp (9.0); Capex intensity ±15% (4.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 18×, FY+5 revenue $4B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth (YoY) < 0.015 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Base case assumes ~5% organic growth off normalised procedure and biopharma R&D demand. Two prints below ~1.5% would place the mix between the base and the Hospital-Capex/Utilization recession path, undermining the volume-recovery premise.
• Non-GAAP operating margin < 0.22 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Base op margin is 23.6%. A drift below ~22% sustained two quarters signals pricing or mix pressure consistent with the cyclical-downturn path (20.5%) rather than mid-cycle economics.
• Biopharma / life-science-tools segment order growth < 0.0 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Reagents and instrument demand track biopharma R&D budgets. Two quarters of declining orders would corroborate a funding-reset state and pull the weighting away from the base toward the reset paths.
• FY guidance revision (revenue midpoint) < 3.0 (single event → Reimbursement / Funding / Utilization Reset). Reconciliation carries an FY revenue guide of $3.1B. A cut of the midpoint below ~$3.0B would break the mid-cycle revenue path the base target rests on.
• Net-debt / EBITDA > 3.0 (2 consecutive prints → Mid-Cycle — Procedure & R&D Demand). Net debt is ~$2.49B against EBITDA that supports the capital-return case. Leverage sustained above ~3x would constrain buybacks and force a re-rating of the capital-allocation premise embedded in the base multiple.

Fact / Inference / Speculation

• FACT: Spot $112; 52-week range $81–$118; engine rating HOLD; base-case target $113 (+1%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $97 (-13% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $97 (-13% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.